Yesterday, on July 19, 2023, the CFTC held its second voluntary carbon markets convening, approximately a year following the initial voluntary carbon markets convening on June 2, 2022.

Rich Moche talks about an innovative approach to maximizing the value of a distressed asset.

The SEC Chairman Elisse Walter has at long last indicated, in testimony for the Senate Banking Committee, that the SEC’s final regulations regarding "municipal advisors" will "address, the need for an exception" to the definition of "municipal advisor" for appointed board members of municipal securities issuers.

Seth Goldman explains how derivative action litigation can be an effective strategy for minority shareholders and discusses the favorable settlement Mintz achieved on behalf of client FragranceNet.com using this approach.

Advance refundings may be an appropriate target for the semi-jocund question, "sure it works in practice but does it work in theory?".

The court stated clearly that the answer to that question is "No" and that notice of commercial marketing is always required after FDA's date of licensure for the biosimilar.

Bill Hicks was a guest on Between the Biotech Waves with Nessan Bermingham. In this episode, they discuss the state of the capital markets, financing options for companies and the challenges companies face in this market.

In today’s challenging health care environment, Charitable Patient Assistance Programs have emerged to meet the needs of the nearly 30 million Americans that are underinsured.

In today’s challenging health care environment, Charitable Patient Assistance Programs have emerged to meet the needs of the nearly 30 million Americans that are underinsured and have difficulty paying out-of-pocket medical costs.

A small regional hospital’s antitrust suit alleging illegal exclusive dealing and attempted monopolization against its largest competitor will move forward...

The Federal Communications Commission (FCC) released a Public Notice announcing that the application filing window for Round 2 of its COVID-19

Things are drastically changing for covered entities under the 340B program.

2015 promises to be a big year for biosimilars. Our colleague, Thomas Wintner recently published an article in Law360 highlighting the biosimilar developments to expect in 2015 and potential areas for future litigation.

Hospital lawyers, whether in-house or outside counsel, have oversight over many facets of the hospital's operations. One department they may not be focused on, but should be, is the hospital's laboratory.

The clinical laboratory community is dismayed by a last minute, $2.7 billion cut to the Medicare Clinical Laboratory Fee Schedule (CLFS) to help finance the payroll tax and SGR deal. The deal passed both the House and the Senate today.

CMS wants to change the way that it rewards non-qui tam whistleblowers who report alleged fraudulent or unlawful conduct related to Medicare or Medicaid.

The CMS has released its 2014 Final Call Letter for the Medicare Advantage and Medicare Part D programs.

Yesterday CMS released the Medicare Physician Fee Schedule Final Rule for CY 2012, along with a press release and fact sheet summarizing key issues

ML Strategies has posted its weekly Health Care Update. This week's Health Care Update focuses on the latest Congressional developments on the repeal of the Medicare Sustainable Growth Rate...

Many states prohibit or limit the corporate practice of medicine, either through statute or common law.